What is MPowder?
MPowder operates at the intersection of biotechnology and consumer wellness, specializing in targeted supplementation for peri-menopause, menopause, and postmenopause. The company distinguishes itself through a holistic methodology that integrates modern clinical research with natural ingredient profiles to address systemic symptoms such as hormonal fluctuations, metabolic shifts, and mood instability. By offering personalized consultations and a robust digital community, MPowder has transitioned from a niche startup to a recognized authority in the women's health sector. Their market position is reinforced by a commitment to transparency and efficacy, effectively bridging the gap between traditional pharmaceutical interventions and lifestyle-based health management. As the demand for specialized midlife health solutions continues to rise, MPowder remains at the forefront of the industry, utilizing data-driven insights to refine its product formulations and expand its reach to a global demographic of women seeking evidence-based support.
How much funding has MPowder raised?
MPowder has raised a total of $649K across 1 funding round:
Angel/Seed
$649K
Angel/Seed (2020): $649K with participation from Founders Factory, Pink Salt Ventures, and Carrie Longton
Key Investors in MPowder
Founders Factory
Founded in 2015, Founders Factory was established to help early-stage companies rapidly become viable and sustainable businesses. The company is headquartered in the United Kingdom.
Pink Salt Ventures
Pink Salt Ventures is a London-based pre-seed fund focused on investing in female-led technology companies. The firm partners with aspiring entrepreneurs to build lasting businesses while providing guidance and support throughout their journeys.
Carrie Longton
An individual investor providing strategic support and capital to early-stage ventures within the health and wellness sector.
What's next for MPowder?
With this major enterprise-level funding, MPowder is poised to enter a new phase of growth, focusing on product diversification and the expansion of its digital health ecosystem. The strategic allocation of capital will likely prioritize the scaling of supply chain infrastructure to meet increasing consumer demand while simultaneously investing in clinical validation studies to further solidify their market authority. Furthermore, the company is expected to enhance its personalized consultation services, leveraging the recent investment to integrate advanced diagnostic tools that provide users with more granular health insights. By fostering deeper engagement within its community and exploring potential partnerships with healthcare providers, MPowder is strategically aligning itself to capture a larger share of the burgeoning menopause health market, ensuring long-term sustainability and continued innovation in the FemTech space.
See full MPowder company page
